Levopa

Quick links to important sections

Levopa

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levopa

Quick Facts

Property Description
Active ingredients Levodopa and Carbidopa
Form Oral Tablet
Pharmacological Class Dopaminergic Antiparkinsonian Agent
Origin/Type Synthetic, Fixed-Dose Combination

What Type of Medicine is Levopa? (Identity and Classification)

Levopa is a prescription-only medicine that is formally identified as the Co-careldopa combination, which belongs to the class of dopaminergic antiparkinsonian agents. This preparation is a synthetic fixed-dose combination tablet intended for oral administration, containing the two essential components, Levodopa and Carbidopa.

This formulation is structurally defined by its reliance on a dual-component mechanism, a key feature separating it from single-agent therapies. As a compound classified within the CNS (Central Nervous System) agent group, its primary purpose is the systemic delivery of the precursor necessary to address neurochemical deficits. This strategy is clinically recognized for efficacy in improving motor symptoms, making the combination a cornerstone in therapeutic protocols.

Composition: A Dual-Component Mechanism

The core composition consists of Levodopa, which is an Aromatic L-amino acid and the essential dopamine precursor, paired with Carbidopa, a non-crossing decarboxylase inhibitor. The product is completed with pharmaceutical-grade excipients necessary for the tablet formulation.

The specialized function of Carbidopa is entirely peripheral—it does not cross the blood-brain barrier and has no direct central effect. Its role is to protect the Levodopa by preventing its premature breakdown outside the brain through the inhibition of peripheral decarboxylation, which substantially increases the amount of active drug available to the brain.

General Purpose and Therapeutic Principle

The overarching therapeutic principle of this fixed-dose combination is dopamine replacement therapy, designed to counteract a specific neurochemical depletion. The medication's action supports the re-establishment of more balanced dopamine levels in the brain, which is the primary goal of the treatment.

The general benefit of this systemic delivery is to help achieve and support improved motor function and coordination in adults with movement disorders. This combination serves an established and essential role as a foundational therapy for managing movement-related challenges.

Regulatory References

  1. Levodopa and Carbidopa: MedlinePlus Drug Information
  2. WHO Essential Medicines List - Parkinson disease
  3. Levodopa + Carbidopa on WHO Essential Medicines List

What side effects are possible with Levopa?

Adverse reaction scope

Category Description
Key adverse reaction categories Central Nervous System effects (Dyskinesias, Somnolence, Psychiatric disturbances), Gastrointestinal effects (Nausea, Vomiting), and Cardiovascular effects (Orthostatic hypotension).
Frequency classification Very Common: Dyskinesia (Involuntary movements). Common: Confusion, dizziness, somnolence, insomnia, orthostatic hypotension, nausea, vomiting, constipation. Rare: Sudden onset of sleep, psychotic episodes, gastrointestinal hemorrhage, hemolytic and non-hemolytic anemia, malignant melanoma (activation/occurrence).
System-organ classes involved Nervous System, Psychiatric, Gastrointestinal, Cardiovascular, Blood/Lymphatic, and Skin/Subcutaneous systems are associated with documented adverse reactions.
Serious adverse reactions (as documented in regulatory sources) The regulatory label documents the risk of a Neuroleptic Malignant Syndrome (NMS)-like Symptom Complex upon abrupt withdrawal, Sudden onset of sleep during daily activities, and the development of Suicidal tendencies/thoughts.
Population-specific safety considerations (if applicable) Contraindicated in individuals with Narrow-Angle Glaucoma, a history of Malignant Melanoma, or suspicious, undiagnosed skin lesions. Caution is necessary for patients with a history of Peptic Ulcer or severe Cardiovascular Disease.
Dose- or exposure-related patterns (if explicitly stated) The combination may lead to dyskinesias appearing sooner and at lower dosages than with Levodopa alone. Orthostatic effects are often more prominent at treatment initiation.
Safety-related restrictions or limitations Contraindicated for concomitant use with non-selective Monoamine Oxidase (MAO) inhibitors. The medicine may also cause physiological pigmentation change (darkening of urine, sweat, or saliva).

Safety classifications (high-level)

Category Description
Regulatory frequency framework used The official safety communication uses standard regulatory frequency bands (e.g., ICH/EMA/FDA standards) to categorize the likelihood of reported adverse effects.
Regulatory basis Official Prescribing Information / Summary of Product Characteristics (SmPC/FDA DailyMed) of the Levodopa/Carbidopa fixed-dose combination.
Context-of-use safety notes (as defined in official documents) Abrupt withdrawal is restricted due to the serious risk of a withdrawal-emergent hyperpyrexia and confusion syndrome (NMS-like).

Resulting safety structure

  • The official safety profile is characterized by a high frequency of motor (dyskinesia) and gastrointestinal adverse reactions.
  • Regulatory documents specify the risk of serious, high-impact events such as the NMS-like reaction upon abrupt withdrawal and the potential for sudden onset of sleep.
  • The profile includes clear contraindications relating to pre-existing conditions (melanoma, glaucoma) and the concomitant use of certain other drug classes (MAO inhibitors).

Connection to the overall safety profile (2–4 sentences): The official safety profile structures the understanding of the medicine's risk by defining involuntary movements (dyskinesias) as the most frequently documented adverse effect, establishing it as a core safety consequence of treatment. The profile further mandates that the serious risks associated with abruptly stopping the medicine and the defined contraindications for specific co-morbidities must be communicated as central safety constraints. The regulatory framework thus focuses on the frequency, severity, and context-dependent nature of the possible adverse effects.

Overdose and Emergency Response

Overdose: When to Seek Help

Official regulatory documents define the overdose profile for this medication based strictly on reported clinical experiences. An overdose of Levopa is primarily characterized by the exaggerated pharmacological effects of the drug.

Documented Overdose Manifestations

The most prominent signs of excessive intake include involuntary movements, known as dyskinesia. Overdose can also affect the cardiovascular system, potentially leading to cardiac irregularities (arrhythmias) and significant changes in blood pressure, such as orthostatic hypotension (a drop in blood pressure upon standing). Central nervous system (CNS) effects, including confusion or agitation, have also been reported.

Accidental ingestion and poisoning have been reported in the paediatric population. For extended-release formulations, the patient may need prolonged observation due to the risk of delayed or recurring symptoms occurring up to 48 hours after ingestion.

Emergency Response and Management

Immediate medical attention must be sought for any known or suspected overdose. Individuals should be transported to an emergency department for close observation and supportive care. Official regulatory information states that there is no specific antidote for this medication's overdose. Treatment is limited to symptomatic and supportive medical care, which may include maintaining vital functions and attention to the respiratory, circulatory, and renal systems. Intensive monitoring and management, such as gastric lavage and continuous electrocardiogram (ECG) monitoring, may be required.

Therapeutic Uses of Levopa

Quick Facts: Main Therapeutic Domains

  • Condition Management: Management of Parkinson's disease and related syndromes.
  • Symptom Relief: Addresses slow movement (bradykinesia) and rigidity.
  • Targeted Use: Utilized for parkinsonism following encephalitis or intoxication (e.g., carbon monoxide).

Levopa is a medication commonly used to assist in the management of the motor symptoms associated with Parkinson's disease. Its primary therapeutic goal is to help alleviate the characteristic slow movement, stiffness, and rigidity that can accompany the condition. The medication is an established option intended to support and improve a person's functional capacity and overall ability to perform daily activities.

Levopa is also indicated for the treatment of specific symptomatic parkinsonism, such as those that may be observed following inflammation of the brain (post-encephalitic parkinsonism) or conditions resulting from specific types of intoxication, like carbon monoxide or manganese exposure. This treatment is intended to help control motor fluctuations and is considered a foundational part of the care regimen for this progressive neurological disorder.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Levopa (carbidopa/levodopa) is approved for use in adult patients but is subject to several strict regulatory constraints and contraindications based on patient history and concurrent conditions.

Formal Contraindications

The medicine is formally contraindicated and must not be used in the following populations:

  • Patients with a known hypersensitivity to any component of Levopa.
  • Patients with narrow-angle glaucoma.
  • Patients with suspicious, undiagnosed skin lesions or a history of malignant melanoma.
  • Patients currently taking a nonselective monoamine oxidase (MAO) inhibitor or who have discontinued one within the past two weeks.

Specific Population Restrictions

Population/Condition Eligibility Status (Regulatory Basis)
Pediatric Use (Under 18) Not established; safety and effectiveness have not been demonstrated.
Pregnancy Not recommended unless the benefit clearly outweighs the potential risk of fetal harm (based on animal data).
Lactation Discontinuation of either the drug or breastfeeding is required.
Severe Organ Disease Use requires caution in patients with severe cardiovascular, pulmonary, renal, hepatic, or endocrine disease.
Psychotic Disorder Patients with a major psychotic disorder should ordinarily not be treated due to the risk of exacerbating the condition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formal Restrictions and Timing

Levopa is contraindicated for use with nonselective Monoamine Oxidase (MAO) Inhibitors due to the serious risk of developing severe hypertension (hypertensive crisis). To prevent this interaction, nonselective MAO inhibitors must be discontinued for a minimum of two weeks before Levopa therapy is initiated. The therapeutic effect of Levopa may be reduced by co-administering Dopamine D2 Receptor Antagonists, a group that includes certain antipsychotic medicines.

Exposure and Absorption Interference

The absorption of Levopa is influenced by various substances. Iron salts (e.g., Ferrous Sulfate), often found in vitamin supplements, decrease the bioavailability of Levopa due to binding in the gastrointestinal tract; therefore, administration should be separated. Ingestion of high-protein food may also impair the amount of Levopa absorbed due to competition with amino acids for intestinal transport. Conversely, COMT Inhibitors increase the plasma levels and half-life of Levodopa. The Carbidopa component in Levopa protects Levodopa from the accelerating breakdown effect of Pyridoxine (Vitamin B6), allowing for co-administration.

Pharmacodynamic Considerations

Combining Levopa with antihypertensive agents may lead to an additive effect resulting in postural hypotension (a drop in blood pressure when standing). Additionally, alcohol (Ethanol) consumption may potentiate the central nervous system effects of Levopa, increasing somnolence.

Mechanism of Action

Central Dopamine Precursor Delivery and Activation

This mechanism begins with Levodopa, which acts as a precursor that is transported across the blood-brain barrier (BBB) via the LNAAT transporter system. Once within the central nervous system, Levodopa is converted into the active neurotransmitter, Dopamine, primarily by the enzyme Aromatic L-amino acid decarboxylase (AADC) in presynaptic neurons. Dopamine then acts as an indirect agonist, stimulating postsynaptic Dopamine Receptors ( D1 and D2) in the striatum. This pathway modulation is the mechanism that results in a modified signaling pattern in the motor control circuitry.

Peripheral Enzyme Protection and Functional Synergy

This complementary action addresses the role of Carbidopa, a non-crossing, irreversible inhibitor of the AADC enzyme in the periphery. By blocking the premature breakdown of Levodopa outside the CNS, Carbidopa ensures that a greater proportion of the precursor reaches the brain. This functional enhancement of Levodopa delivery is an essential mechanistic synergy that optimizes central neurochemical repletion while preventing the formation of peripheral dopamine.

Limitations Based on Transport and Synthesis Capacity

The effectiveness of the mechanism is physiologically constrained by Competitive Transport, where Levodopa uptake is subject to competition from other large neutral amino acids (LNAAs). Furthermore, its conversion relies on the functional integrity and survival of presynaptic neurons containing the central AADC enzyme. These constraints directly influence the characteristics of the resulting motor control modulation.

Dosage and Administration Information

The Levodopa/Carbidopa combination (Co-careldopa) is available for administration primarily through the oral route as a tablet or capsule, but an intestinal suspension administered via a PEG-J tube is also used in advanced therapy.

Therapy initiation starts with a low initial dosage for immediate-release tablets (e.g., 25 mg carbidopa/100 mg levodopa three times a day) which is gradually titrated (adjusted) over time based on the response. The tablets are administered in divided doses multiple times throughout the day, ensuring a minimum of 70 mg to 100 mg of Carbidopa per day to support intended action, though the maximum total daily dose of the combination is limited.

Administration is permissible with or without food, although taking it with high-protein, high-fat meals may delay absorption of the active component. Crucially, the extended-release forms must be swallowed whole and must not be crushed, divided, or chewed. Furthermore, patients converting from Levodopa-only therapy typically cease taking it for at least 12 hours before starting Co-careldopa. It is essential that the daily dosage should never be stopped abruptly or reduced rapidly; treatment cessation requires gradual tapering. Special attention is given to age-group rules, with use in children typically reserved for physician determination only. The protocol defines a structured approach emphasizing cautious initiation, dose flexibility via titration, consistent daily frequency, and controlled discontinuation.

Recent Clinical Evidence

Research evidence / Overview of Studies for Levopa

Evidence for Use in Idiopathic Parkinson's Disease

The available research includes Randomized Controlled Trials (RCTs). These RCTs are studies where participants are randomly assigned to receive either the medicine or a control group to help researchers examine outcomes related to physical discomfort. Studies exploring short-term symptom changes typically lasted several months, and many were double-blind. Research examined core motor symptoms, such as rigidity and slowness of movement, using standardized rating scales. Studies reported patterns in how symptoms evolved during the study period when compared to control groups. Findings describe patterns observed in the studies related to outcomes in daily functioning or activity level in the observed populations. This evidence contributes to the broader evidence landscape regarding how symptoms are studied in conditions marked by functional limitations.

Evaluating Outcomes in Advanced Parkinson's Disease

For individuals with more advanced Parkinson's disease who experience periods of fluctuating symptoms, research has explored the combination’s role in managing these episodic or acute changes. Studies were conducted during periods of increased symptom activity, focusing on time intervals where symptoms become more noticeable—known clinically as "off" time. Researchers monitored outcomes related to physical discomfort. The findings indicate patterns related to measured time intervals for "off" periods and "on" time, which describes periods of varying mobility. Studies also monitored the emergence of involuntary movements, or dyskinesia, which was associated with the treatment in some studies.

Evidence for Use in Symptomatic Parkinsonism

Research also describes the use of Levodopa/Carbidopa for specific forms of secondary or symptomatic parkinsonism. The evidence for this indication relies on historical clinical descriptions and Case Reports/Series, rather than modern, large-scale RCTs. Findings describe patterns observed in these small, specific populations, with changes in symptoms documented in clinical practice.

Long-Term Studies and Durability of Response

To explore sustained outcomes, researchers applied studies examining patient-reported experiences in long-term observational settings evaluating daily-life functioning. Findings describe patterns observed in these longer observational studies related to monitoring of symptoms over time. However, long-term outcomes are not well characterized by blinded RCTs.

Research Gaps and Areas of Uncertainty

The research provides context, but data are still limited in certain areas. The long-term relationship to the overall rate of disease progression is not fully established by the existing controlled evidence. Comparative evidence is lacking in some areas, and results apply only to the specific study populations.

Frequently Asked Questions (FAQ)

Common questions about Levopa (FAQ)


Q: What happens if I forget to take a dose of Levopa?

A: Official administration instructions emphasize taking the medicine as consistently as prescribed and caution against sudden changes or rapid withdrawal. If a dose is missed, patients are typically advised to resume their schedule but should never take a double dose to make up for the missed one, as this may increase the risk of side effects. Information regarding missed doses should be sought from a prescribing professional.


Q: Is it safe to drink coffee while using Levopa?

A: Levopa absorption can be reduced by certain substances, particularly large neutral amino acids found in high-protein foods, due to competition for transport. Because coffee may also contain amino acids, official documents indicate that high-protein intake can reduce the amount of the medicine absorbed, which may lead to fluctuations in response. Consistency in dietary habits may be discussed with a prescribing professional.


Q: Is Levopa safe for people with kidney problems?

A: The medicine is generally used with caution in patients with renal impairment (kidney problems). Official information notes that specific studies on the pharmacokinetics—how the body handles the medicine—have not been detailed for patients with severe kidney or liver disease. Dose adjustment based on the patient's specific condition may be considered.


Q: What do people mean when they talk about the 'wearing off' effect of Levopa?

A: The term 'wearing off' is used to describe when the benefits of the medicine lessen and symptoms return before the next scheduled dose is due. This is a common pattern of motor fluctuation that can occur as the underlying condition progresses, and it is a recognized consideration in the long-term management of the condition.


Q: Can I take Levopa if I have high blood pressure?

A: Official warnings state that Levopa can contribute to postural hypotension, which is a drop in blood pressure that occurs when standing up. For patients already taking medicines for high blood pressure, the use of Levopa is typically handled with caution due to the potential for an additive blood-pressure-lowering effect.


Q: What should I do if I feel dizzy after taking Levopa?

A: Dizziness is a possible sign of orthostatic hypotension (low blood pressure when standing), which is documented as a common adverse reaction in regulatory safety profiles. Official warnings advise monitoring for this effect, especially when treatment begins or when the dose is increased. If this is experienced, communication with a health professional is typically advised.


Q: Is Levopa considered a high-risk medication?

A: Levopa is a medicine that requires careful handling and monitoring. Official documents list several serious warnings, including contraindications for specific patient groups and the risk of serious events like a Neuroleptic Malignant Syndrome-like complex if the medicine is abruptly stopped. Use of the medicine typically involves careful patient monitoring and adherence to prescribing guidelines.


Q: Does Levopa need to be taken at the exact same time every day?

A: Official instructions specify that the medicine must be taken in divided doses multiple times throughout the day to achieve and maintain a consistent therapeutic effect. While the requirement is not for the exact same second, consistency in the dosing schedule is emphasized as important for effective symptom management.


Q: Is there any evidence about Levopa use during pregnancy?

A: Official information regarding pregnancy is based primarily on animal studies. The medicine is generally not recommended for use during pregnancy. Official documents state that use is considered only when the potential benefit is judged to outweigh the potential fetal risk.


Q: Can Levopa be safely used while breastfeeding?

A: Official guidance states that because the medicine or its by-products may pass into human milk, a decision must be made to discontinue either the medicine or the breastfeeding process itself. This is a safety measure addressed in regulatory documentation.


Q: Does Levopa cause hair loss?

A: Yes, alopecia (hair loss) is listed in regulatory documents as a possible adverse reaction associated with the use of Levopa.


Q: Are there any reported interactions between Levopa and herbal supplements?

A: While regulatory documents do not list every single herbal supplement, they specifically warn of interactions with certain compounds often found in them. Notably, Iron salts and Pyridoxine (Vitamin B6) can interfere with how Levopa is absorbed or utilized. Disclosure of all supplements to a health professional is necessary for safe prescribing.


Q: How does my age impact how Levopa works?

A: Official documents note that older patients (geriatric population) may exhibit increased sensitivity to a given dose. This is often due to natural age-related changes in the body, such as reduced clearance, which can result in higher amounts of the active component being available in the system.


Q: What kind of monitoring might a doctor do while I'm on Levopa?

A: During treatment, monitoring may be carried out by the doctor. This can include assessments for signs of postural hypotension, checking for changes in mental or psychiatric status, observing for new or worsened involuntary movements (dyskinesias), and periodically monitoring organ function.


Q: Does Levopa affect my reaction time or ability to drive?

A: Yes, official warnings state that the medicine may cause somnolence (drowsiness) and, in rare instances, a sudden onset of sleep during daily activities. Patients are advised that these effects can impair their ability to perform tasks requiring full vigilance, such as operating machinery or driving.


Q: Can I take other prescription medications while using Levopa?

A: Co-administration with many other prescription medications is common, but strict regulatory warnings must be followed. Some drug classes are contraindicated (e.g., nonselective MAO inhibitors) and others require caution (e.g., antihypertensives). A prescribing professional should always be informed of all current and planned medications.


Q: Why is it important to tell my doctor about all the supplements I take when starting Levopa?

A: It is important because specific supplements, especially those containing iron salts or large amounts of Pyridoxine (Vitamin B6), can interfere with the absorption or effectiveness of Levopa. This interference is documented in official regulatory interactions information.


Q: Does Levopa cause weight gain or weight loss?

A: Regulatory documents list weight loss as a documented adverse reaction associated with the use of Levopa.


Q: Are there long-term side effects associated with taking Levopa?

A: Official safety profiles document that Dyskinesias (involuntary movements) are a very common adverse reaction. This effect can appear or become more prominent with continued, long-term treatment, making it a key focus of ongoing monitoring.


Q: Can Levopa be used by older adults?

A: Official documents confirm the medicine is indicated for use in adults, including older adults. However, official documents suggest that use in older individuals may necessitate caution, as they can sometimes be more sensitive to the medicine's effects.


Q: Is it normal to feel a bit restless after starting Levopa?

A: The regulatory label reports psychiatric adverse reactions including Confusion, Agitation, and Anxiety, which can be experienced as feelings of restlessness. These types of effects are often monitored by a health professional, particularly during the initial phase of treatment.


Q: How quickly should I expect Levopa to start making a difference?

A: For some patients, a positive response may be observed within a day, or even after a single dose. Official information from clinical trials suggests that fully effective dose levels are typically established within about seven days after the initial dose adjustment (titration) process begins.


Q: Is it true that Levopa has an interaction with iron supplements?

A: Yes, official regulatory documents confirm that iron salts (like ferrous sulfate) found in supplements decrease the bioavailability of Levopa. This occurs because the iron binds to the medicine in the digestive tract, reducing the amount that can be absorbed.


Q: Can Levopa cause strange dreams or hallucinations?

A: Yes, official safety documents list Psychotic episodes, including hallucinations, as well as dream abnormalities and nightmares, among the possible adverse reactions associated with the medicine.


Q: What are the differences between brand-name and generic Levopa?

A: Regulatory guidelines require that a generic version of the medicine must contain the same active ingredients (Levodopa and Carbidopa) and be demonstrated to deliver the same amount of the active component to the body as the brand-name product. This ensures therapeutic equivalence.


Q: What is the scientific basis for Levopa's effectiveness?

A: The scientific basis is known as dopamine replacement therapy. The mechanism involves the precursor Levodopa being delivered to the brain and converted into the neurotransmitter Dopamine. The second component, Carbidopa, works by protecting the Levodopa outside the brain, ensuring a greater amount reaches the central nervous system.


Q: What are the signs of an allergic reaction to Levopa?

A: Signs of a hypersensitivity (allergic) reaction documented in the regulatory profile include skin manifestations like rash, urticaria (hives), and pruritus (itching). More serious signs can include angioedema (swelling). This information is included as a safety precaution in the official drug profile.


Q: Why does Levopa sometimes cause nausea?

A: The nausea and vomiting associated with this medicine are primarily related to the formation of dopamine in the periphery (outside the brain). The component Carbidopa is specifically included in the formulation to inhibit this peripheral conversion, which is intended to minimize these common gastrointestinal side effects.


How should Levopa be stored and disposed of?

How to Store and Dispose of Levodopa/Carbidopa

The storage and disposal of levodopa/carbidopa oral tablets are governed by mandatory regulatory requirements to ensure product stability and safety.

Storage Requirements

  • Temperature: Store at Controlled Room Temperature (ideally 20^circ to 25 C or 68^circ to 77 F), with excursions permitted up to 30 C. Some formulations specify not to store above 25 C.
  • Environmental Protection: The medicine must be protected from light and moisture.
  • Container: Store in a tightly closed container and maintain it in the original package.
  • Child Safety: All formulations must be kept out of the sight and reach of children.

Disposal Instructions

  • Discarding Product: Any unused or expired medicine and associated waste materials must be disposed of in accordance with local, national, and regional requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levopa found in:

A-Z Index: